SCHEDULE: Commodore Capital Reduces Stake in Viridian Therapeutics
Beneficial Ownership Amendment
Commodore Capital LP and Commodore Capital Master LP have reduced their beneficial ownership in Viridian Therapeutics, Inc. to 3.9% of common stock.
Summary
- Commodore Capital LP and Commodore Capital Master LP filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Viridian Therapeutics, Inc.
- As of September 30, 2025, the reporting persons beneficially own an aggregate of 3,200,000 shares of Viridian Therapeutics' Common Stock.
- This represents 3.9% of the issuer's outstanding common stock, based on 82,229,158 shares reported as outstanding on September 30, 2025.
- Commodore Capital LP acts as the investment manager for Commodore Capital Master LP, with Michael Kramarz and Robert Egen Atkinson exercising investment discretion.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the reduction in institutional ownership below the 5% threshold, which can be interpreted as a decrease in confidence or a strategic divestment, although the filing itself is a neutral disclosure.
Positives
- NA
Negatives
- The filing indicates a reduction in beneficial ownership by Commodore Capital LP and Commodore Capital Master LP to below the 5% threshold, which could be interpreted as a decrease in institutional confidence or a portfolio rebalancing.
Risks
- NA
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or the reporting persons' future investment intentions beyond the current ownership disclosure.
Management Comments
- NA
Industry Context
This filing reflects a change in institutional ownership for Viridian Therapeutics, a common occurrence in the biotechnology or pharmaceutical sector where investment firms frequently adjust their positions based on clinical trial results, regulatory milestones, or market conditions. A reduction in stake by an institutional investor can sometimes signal a re-evaluation of the company's prospects relative to other opportunities in the sector.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The reduction in a significant institutional stake could lead to concerns about the company's valuation or future prospects, potentially influencing trading behavior.
- Management: May need to address investor sentiment if the reduction is perceived negatively by the market.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which required the filing of this statement, reflecting the ownership stake. |
| 11/05/2025 | Date Viridian Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting 82,229,158 Common Shares outstanding. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed by Commodore Capital LP and Commodore Capital Master LP. |
Recommendation
holdThe filing indicates a reduction in beneficial ownership by a significant institutional investor to below 5%. While not a direct negative, it suggests a potential re-evaluation of the investment by Commodore Capital. Without further context on the reasons for the reduction or the investor's previous stake, a 'hold' recommendation is prudent, advising investors to monitor future developments and the company's performance.
Keywords
Viridian Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Institutional Investment, Equity Stake, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.